RAD52 motif‑containing protein�1 promotes non‑small cell lung cancer cell proliferation and survival via cell cycle regulation

Xu, Guihua; Du, Jiya; Wang, Feng; Zhang, Fan; Hu, Ruimin; Sun, Dejun; Shen, Jie

doi:10.3892/or.2018.6459

Cited by 6 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we identified a novel oncogene, RDM1, mediating the progression of NB, supporting the role of RDM1 in cell proliferation and tumorigenesis. Since DNA repair protein RAD52 has previously been implicated in the development of resistance to cancer therapy [22], RDM1 was initially indicated to have a similar function to RAD52 in DNA repair pathways [16]. Our Oncomine-based (TCGA database) expression analyses and IHC staining in clinical tumor samples confirmed that RDM1 was high expressed.…”

Section: Discussionsupporting

confidence: 61%

“…Previous work showed the regulation of RDM1 in lung cancer [16] and papillary thyroid carcinoma [17]. However, in this study, we identified RDM1 as an oncogenic target in NB.…”

Section: Discussioncontrasting

confidence: 60%

“…The repair of double‐strand breaks (DSBs) is mediated by RAD52‐dependent recombination and the genomic integrity resulted from dysfunctional DNA damage response (DDR) signaling in the DNA repair pathways . RDM1 was found to have function in lung cancer and papillary thyroid carcinoma , but its function in NB progression remains unclear.…”

mentioning

confidence: 99%

See 2 more Smart Citations

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway

Xie

Cai

et al. 2019

FEBS Open Bio

View full text Add to dashboard Cite

Neuroblastoma ( NB ) is an aggressive cancer that originates in the sympathetic nervous system and primarily affects children. Here, we show that high levels of RAD 52 motif containing 1 ( RDM 1; a protein with similarities to RAD 52, which is important for double‐strand DNA repair) are associated with poor clinical outcomes for NB . In addition, RDM 1 −/− cells exhibited increased sensitivity to cisplatin, a common chemotherapy drug, and disruption of RDM 1 suppressed NB cell proliferation. We also report that loss of RDM 1 augmented cell apoptosis and induced cell cycle arrest, and that stable knockdown of RDM 1 significantly inhibited NB tumor growth in a xenograft mouse model. Importantly, we identified that RDM 1 promoted cell proliferation via the RAS –Raf–mitogen‐activated protein kinase kinase ( MEK )–extracellular signal‐regulated kinase ( ERK ) signaling pathway. In conclusion, the current study demonstrates a correlation between DNA damage regulator RDM 1 and the oncogenic RAS –Raf– MEK – ERK pathway in NB .

show abstract

Section: Discussionsupporting

confidence: 61%

“…Previous work showed the regulation of RDM1 in lung cancer [16] and papillary thyroid carcinoma [17]. However, in this study, we identified RDM1 as an oncogenic target in NB.…”

Section: Discussioncontrasting

confidence: 60%

See 1 more Smart Citation

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway

Xie

Cai

et al. 2019

FEBS Open Bio

View full text Add to dashboard Cite

show abstract

“…RDM1 −/− cells have been reported to exhibit increased sensitivity to cisplatin . Recently, two different research groups have shown that RDM1 exhibits significant up‐regulation in human lung adenocarcinoma . Accordingly, RDM1 and RAD52 have been proposed to share similar functions in both homologous recombination as well as DNA double‐strand break repair.…”

Section: Introductionmentioning

confidence: 99%

“…9 Recently, two different research groups have shown that RDM1 exhibits significant up-regulation in human lung adenocarcinoma. 10,11 Accordingly, RDM1 and RAD52 have been proposed to share similar functions in both homologous recombination as well as DNA double-strand break repair. Notably, RDM1 can regulate p53/ RAD51/RAD52, and its down-regulation of p53 is involved in lung adenocarcinoma.…”

Section: Introductionmentioning

confidence: 99%

RDM1 promotes critical processes in breast cancer tumorigenesis

Chen

Sun

Zhong

2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Breast cancer is currently among the most common cancers in women, with almost 200,000 new cases diagnosed annually. Dysregulation of DNA repair pathways allows cells to accumulate damage and eventually mutations, with a subsequent reduction in DNA repair capacity in breast tissue, leading to tumorigenesis. One component of the DNA damage repair pathway is RAD52 motif‐containing 1 (RDM1), but the specific role of RDM1 in breast cancer and the underlying mechanism remain unclear. Here, we examined the role played by RDM1 in breast cancer cell culture using the HBL100 and MCF‐7 breast cancer cell lines. Disruption of RDM1 reduced in vitro cell proliferation and promoted apoptosis. Knockdown of RDM1 also induced up‐regulation of p53 levels, whereas RAD51 and RAD52, both involved in DNA repair, were down‐regulated. In addition, the in vivo growth of RDM1‐deficient cells was significantly repressed, suggesting that RDM1 is a novel oncogenic protein in human breast cancer cells. This study reveals a link between the DNA damage response pathway and oncogenic functionality in breast cancer. Accordingly, therapeutic targeting of RDM1 is a potential treatment strategy for breast cancer and overcoming drug resistance.

show abstract

Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma

Qiu

Cao

et al. 2021

Bioscience Reports

View full text Add to dashboard Cite

Purpose: Hepatocellular carcinoma (LIHC) is one of the most common primary malignant liver tumors worldwide. The RAD52 motif-containing protein 1 (RDM1) has been shown to play a role in mediating DNA damage repair and homologous recombination. This study was designed to determine the expression of RDM1 and its prognostic value as well as its relationship with immune infiltration in LIHC patients. Methods: Oncomine and Tumor Immunoassay Resource were used to assess the expression of RDM1. PrognoScan and Kaplan-Meier bioinformatics database were used to analyze the impact of clinical influencing factors on prognosis. Finally, the TIMER and GEPIA databases were used to detect the correlation between expression of RDM1 and expression of marker genes related to immune infiltration. Immunohistochemistry (IHC) method was used to detect the expression level of RDM1 in 90 cases of hepatocellular carcinoma and adjacent normal liver tissues. Results: RDM1 expression was upregulated in most cancers. The expression of RDM1 was remarkably higher than that of the corresponding normal control genes in LIHC tissues. The increase in RDM1 mRNA expression was closely related to the decreases in overall survival and progression-free survival. Additionally, the increase in RDM1 mRNA expression was closely related to the infiltration levels of macrophages, CD8+ T cells and B cells and was positively correlated with a variety of immune markers in LIHC. Conclusion :The findings of this study demonstrate that RDM1 is a potentially valuable prognostic biomarker that can help determine the progression of cancer and is associated with immune cell infiltration in LIHC.

show abstract

RAD52 motif‑containing protein�1 promotes non‑small cell lung cancer cell proliferation and survival via cell cycle regulation

Cited by 6 publications

References 26 publications

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway

RDM1 promotes critical processes in breast cancer tumorigenesis

Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma

Contact Info

Product

Resources

About